Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Moss MC et al. | Lithium use for bipolar disorder post renal transplant: is mood stabilization without toxicity possible? | 2014 | Transplantation | pmid:24492429 |
Fridell JA et al. | Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. | 2006 | Transplantation | pmid:16906038 |
Narayanan M et al. | Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. | 2013 | Transplantation | pmid:23423268 |
Reutzel-Selke A et al. | Short-term immunosuppressive treatment of the donor ameliorates consequences of ischemia/ reperfusion injury and long-term graft function in renal allografts from older donors. | 2003 | Transplantation | pmid:12811235 |
Trancassini M et al. | Microbiologic investigation on patients with cystic fibrosis subjected to bilateral lung transplantation. | 2001 | Transplantation | pmid:11707748 |
Woodle ES et al. | FK506--reversal of humorally mediated cardiac allograft rejection in the presence of preformed anti-class I antibody. | 1993 | Transplantation | pmid:7504346 |
van Hooff JP | Pneumocystis carinii pneumonia after renal transplantation. | 1997 | Transplantation | pmid:9158038 |
Hsiau M et al. | Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. | 2011 | Transplantation | pmid:21857278 |
Roberts JP et al. | Reversal of chronic rejection after treatment failure with FK506 and RS61443. | 1993 | Transplantation | pmid:7692634 |
Kitayama T et al. | Facilitation of tacrolimus-induced heart-allograft acceptability by pretransplant host treatment with granulocyte colony-stimulating factor: interleukin-12-restricted suppression of intragraft monokine mRNA expression. | 2003 | Transplantation | pmid:12605126 |
Cacciarelli TV et al. | Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. | 1996 | Transplantation | pmid:8610416 |
Yu S et al. | Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. | 2006 | Transplantation | pmid:16421475 |
Macphee IA et al. | Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. | 2002 | Transplantation | pmid:12490779 |
MacDonald AS | Management strategies for nephrotoxicity. | 2000 | Transplantation | pmid:10910262 |
Higgins RM et al. | Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. | 2000 | Transplantation | pmid:10836393 |
Podesser BK et al. | Comparison of low and high initial tacrolimus dosing in primary heart transplant recipients: a prospective European multicenter study. | 2005 | Transplantation | pmid:15714171 |
Garton T | Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus1. | 2002 | Transplantation | pmid:12352898 |
Peng Y et al. | Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. | 2013 | Transplantation | pmid:23263506 |
Günther M et al. | Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. | 2001 | Transplantation | pmid:11233913 |
Uemoto S et al. | Experience with FK506 in living-related liver transplantation. | 1993 | Transplantation | pmid:7679528 |